Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics (Nasdaq: BNGO) announced the grant of non-qualified stock options under its 2020 Inducement Plan to new employees including Chief Informatics Officer Soheil Shams, who received options for 400,000 shares. An additional 18 employees received options for a total of 454,000 shares linked to Bionano’s acquisition of BioDiscovery, Inc. All options will vest over four years, starting with 25% at one year from the vesting commencement date of October 18, 2021. The exercise price for the options is set at $5.40 per share, matching the closing stock price on November 1, 2021.
Bionano Genomics (BNGO) will hold a conference call and live webcast on November 4, 2021, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The event will cover recent corporate progress. Participants can join by using the toll-free number 1-877-407-0784 or the international number 1-201-689-8560, entering Conference ID 13724790. An archived version of the webcast will be available on the Bionano website.
Bionano Genomics (BNGO) announced significant advancements in optical genome mapping (OGM) at the American Society of Human Genetics conference. The new capabilities allow the detection of allelic imbalance and absence of heterozygosity (AOH), enhancing the clinical utility of the Saphyr® system. These advancements could improve insights into cancer progression and recessive disorders, potentially increasing adoption among laboratories. CEO Erik Holmlin emphasized the importance of these features for enhancing comprehensive genome analysis.
Bionano Genomics (BNGO) announced participation in the upcoming American Society of Human Genetics (ASHG) conference, from October 18-22, 2021, showcasing customer presentations and posters featuring their Optical Genome Mapping (OGM) technology. Applications span from genetic diseases like ALS to cancer research, including pediatric brain tumors. Key presentations include studies on structural variations in ALS and validation studies of postnatal structural variations. The conference highlights Bionano's commitment to advancing genetic research.
Bionano Genomics (BNGO) has announced a significant study published in the Nature Publishing Journal of Genomic Medicine, demonstrating the effectiveness of its Saphyr system in combination with next-generation sequencing (NGS) for identifying previously unclassifiable genetic diseases. The research highlighted a 40% increase in detection capability, successfully resolving 50% of previously exome-negative cases. The study showcases the potential of Bionano's Full-Genome Analysis (FGA) method to enhance diagnostic accuracy in rare genetic disorders.
Bionano Genomics (BNGO) has announced its acquisition of BioDiscovery, a leader in genomic software solutions, for up to $100 million in cash and equity. This acquisition aims to enhance Bionano's market position in digital cytogenetics and genome analysis by integrating BioDiscovery's NxClinical software. The merger is expected to streamline data analysis for structural variants, significantly reducing processing time from hours to under 20 minutes. Key personnel from BioDiscovery will join Bionano’s leadership team, further driving innovation in genomics.
Bionano Genomics (BNGO) announced the addition of four key individuals to its commercial leadership team, aiming to accelerate the global growth of its Saphyr system. New members include Amanda Lettmann (VP of Global Customer Experience), Amanda Hernandez (VP of Global Sales Training and Development), Justin Leighton (VP and General Manager, Lineagen), and Bob Hertsenberg (North America Sales Director). The team brings diverse experience from leading firms to enhance customer support and drive sales growth, marking a strategic effort to capitalize on Bionano's position in the genomics market.
Bionano Genomics (BNGO) has published a significant clinical study confirming the efficacy of optical genome mapping (OGM) for diagnosing facioscapulohumeral muscular dystrophy (FSHD). This study, the largest of its kind, involved 351 participants and demonstrated OGM's superior speed and accuracy compared to the traditional Southern blot analysis, with a turnaround time of just 5 days versus 11 days. The findings suggest that OGM can reliably identify mutations and improve diagnostic processes for FSHD, which affects muscle strength and function.
Bionano Genomics (Nasdaq: BNGO) announced a study revealing that combining optical genome mapping (OGM) with short-read next-generation sequencing (NGS) enhances genome analysis for lung cancer, particularly in non-small cell lung carcinoma (NSCLC). The research, published in Cell Reports, demonstrates how this combination improves detection of structural variants (SVs) and aids in discovering new oncogenes. The study highlights the vital role of OGM in identifying SVs, which are crucial for understanding cancer development.
Bionano Genomics announced that NuProbe Global has adopted its Saphyr system for optical genome mapping. This integration will enhance NuProbe’s Quantitative Amplicon Sequencing and Blocker Displacement Amplification technologies, aimed at improving genome analysis in reproductive health and oncology. The Saphyr system offers advanced detection of structural DNA variants with high resolution and user-friendly workflows, which are crucial for identifying genetic diseases and cancer. Both companies aim to enhance diagnostic accuracy and patient outcomes through this collaboration.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
